Floatz logo

Us-Atg-F

Adult Acute Myeloid Leukemia

Neovii BiotechPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Adult Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
Wake Forest University Health Sciences
Phase 3BBB
Idarubicine
University of Nebraska
Phase 3BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
Valspodar
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Us-Atg-F is also rated in:

graft versus host diseaseDormant
BB
Indicative ·
64 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
57 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →